Ignite Creation Date:
2024-05-06 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05252416
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2022-01-25
Brief Title:
VELA Study of BLU-222 in Advanced Solid Tumors
Sponsor:
Blueprint Medicines Corporation
Organization:
Blueprint Medicines Corporation
Study Overview
Official Title:
A Phase 12 Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 12 open-label first-in-human FIH study designed to evaluate the safety tolerability pharmacokinetics PK pharmacodynamics PD and anticancer activity of BLU-222 a selective inhibitor of CDK2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None